Merck & Co., Inc.

NYSE MRK

Merck & Co., Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 23.68%

Merck & Co., Inc. EBIT Margin is 23.68% for the Trailing 12 Months (TTM) ending September 30, 2024, a 60.31% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Merck & Co., Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 14.77%, a -50.99% change year over year.
  • Merck & Co., Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 30.14%, a 68.96% change year over year.
  • Merck & Co., Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 17.84%, a -36.79% change year over year.
  • Merck & Co., Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 28.22%, a 4.04% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
NYSE: MRK

Merck & Co., Inc.

CEO Mr. Robert M. Davis J.D.
IPO Date Jan. 13, 1978
Location United States
Headquarters 2000 Galloping Hill Road
Employees 70,000
Sector Health Care
Industries
Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Similar companies

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

PFE

Pfizer Inc.

USD 26.41

-1.46%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

JNJ

Johnson & Johnson

USD 144.75

0.19%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email